Robert Deans, Ph.D.

Chief Technology Officer

Robert Deans, Ph.D., serves as BlueRock’s CTO, where he is responsible for implementing BlueRock’s novel induced pluripotent stem cell production platform. He has more than 25 years of experience in stem cell therapeutics, including hematopoietic as well as mesenchymal stem cell (MSC) cells and gene therapy approaches, as well as translational science and global regulatory expertise. Dr. Deans previously served as CSO of Rubius Therapeutics, where he was responsible for development of a gene-engineered red cell therapeutics platform. Prior to Rubius, he was an EVP at Athersys, where he helped advance numerous adult adherent stem cell therapeutics into late-stage clinical development. Dr. Deans also served as VP of research at Osiris Therapeutics, where he developed Prochymal, which achieved clinical approval in some geographies. Before that he was director of R&D at Baxter Healthcare where he developed biologics, including a clinical-stage retroviral gene therapy. He holds a B.S. from the Massachusetts Institute of Technology and a Ph.D. in microbiology from the University of Michigan. Dr. Deans founded and chaired the International Society for Cellular Therapy’s Commercialization Committee and chaired the Science and Technology Committee of the Alliance for Regenerative Medicine.